



KOPRAN LIMITED
UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30th SEPTEMBER, 2013

Part I Particulars	Quarter ended					Year ended
	30/09/2013	30/09/2013	30/09/2012	30/09/2013	30/09/2012	31/03/2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Net Sales / Income from Operations	7854	5810	6280	13664	11,258	24,330
Other Operating Income	237	160	183	397	315	692
Total Income from operations	8091	5970	6473	14061	11573	25022
Expenditure						
Changes in Inventories of Finished Goods, Work-in-Progress and stocks-in-trade	(371)	(266)	46	(627)	(399)	(408)
Cost of Materials Consumed	4988	3869	3980	8637	7,442	15,823
Purchase of Stock-In-trade	82	80	-	142	-	-
Employee Benefits Expenses	615	524	452	1139	869	2,048
Depreciation	308	303	302	611	598	1,208
Other Expenses	1350	990	1065	2340	1,951	4,129
Total Expenses	6952	6490	5824	12442	10,461	22,800
Profit (Loss) from operations before other income, interest and exceptional items	1,139	480	649	1,619	1,112	2,222
Other Income	2	2	45	4	91	205
Foreign Exchange Gain/ (Loss)	(263)	104	(90)	(159)	(76)	(33)
Profit (Loss) before interest and exceptional items	878	586	604	1,464	1,127	2,394
Finance Cost	375	307	281	682	553	1,188
Profit (Loss) before exceptional items	503	279	323	782	574	1,206
Exceptional items	-	-	-	-	-	-
Profit (Loss) before tax	503	279	323	782	574	1,206
Loss Tax expenses	-	-	-	-	-	-
Net Profit for the period	503	279	323	782	574	1,206
Paid up equity share Capital (Face value Rs 10/-)	3,905	3,905	3,905	3,905	3,905	3,905
Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	8,048
Earning Per Share (EPS) before and after Exceptional Item						
a) Basic	1.29	0.71	0.83	2.00	1.47	3.09
b) Diluted	1.29	0.71	0.83	2.00	1.47	3.09
Part II						
(A) PARTICULARS OF SHAREHOLDING						
Public shareholding						
Number of shares	23956538	23956538	25809523	23956538	25809523	25510073
Percentage of shareholding	61.35%	61.35%	66.09%	61.35%	66.09%	65.33%
Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered						
Number of shares	3352500	1852500	552500	3352500	552500	1852500
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	22.21%	12.27%	4.17%	22.21%	4.17%	13.68%
Percentage of shares (as a % of the total share capital of the company)	8.59%	4.74%	1.42%	8.59%	1.42%	4.74%
b) Non - encumbered						
Number of shares	11740438	13240438	12687453	11740438	12687453	11686903
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	77.79%	87.73%	95.83%	77.79%	95.83%	86.32%
Percentage of shares (as a % of the total share capital of the company)	30.08%	33.91%	32.48%	30.08%	32.48%	29.93%






(B) INVESTOR COMPLAINTS		3 Months ended 30/09/2013				
Pending at the beginning of the quarter		-				
Received during the quarter		-				
Disposed off during the quarter		-				
Remaining unresolved at the end of the quarter		-				
Reporting of Segment wise Revenue, Result and Capital Employed						
Particulars	Quarter ended			Six Months ended		Year ended
	30/09/2013	30/06/2013	30/09/2012	30/09/2013	30/09/2012	31/03/2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment Revenue						
(a) Pharmaceutical	8,207	6,110	6,693	14,317	11,958	25,734
(b) Consumer Care Division	75	42	-	117	-	-
Total	8,282	6,152	6,693	14,434	11,958	25,734
Less Inter-Segment Revenue	-	-	-	-	-	-
Loss, Excise Duty	191	182	220	373	385	712
Net Sales/ Income from Operation	8,091	5,970	6,473	14,061	11,573	25,022
2. Segment Results						
(a) Pharmaceutical	951	615	603	1,566	1,127	2,394
(b) Consumer Care Division	(73)	(29)	-	(102)	-	-
Total	878	586	603	1,464	1,127	2,394
Less Finance Cost	375	307	281	662	553	1,100
Total Profit Before Tax	503	279	322	782	574	1,206
3. Capital Employed						
(a) Pharmaceutical	19,027	18,167	17,301	19,827	17,301	17,631
(b) Consumer Care Division	196	35	-	196	-	-
(c) Others (Unallocated)	5,424	5,481	5,390	5,424	5,390	5,419
Total	25,447	23,683	22,691	25,447	22,691	23,050
Notes:-						
(1) The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 13th November, 2013. Limited review has been carried out by statutory auditor of the company.						
(2) Auditors observation:						
a) Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd (KRL) as at 30-09-2013 amounting to Rs. 5237.23 Lacs, (as at 30-09-2012 Rs 5202.96 Lacs) are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management, no provision is required to be made because the investment in the Subsidiary Company, KRL, is long term, for strategic reasons.						
(3) Figures for the previous accounting period have been regrouped wherever necessary.						





(4) Statement of Assets and Liability		
Particulars	(₹. in lakhs)	
	As at 30-09-2013	As at 31-03-2013
	Unaudited	Audited
I. EQUITY AND LIABILITIES		
1. Shareholders Funds		
(a) Share Capital	4763	4763
(b) Reserves and Surplus	8830	8048
Total	13593	12811
2. Non-current liabilities		
(a) Long-term borrowings	6920	6948
(b) Long-term provisions	368	157
Total	7288	7305
3. Current liabilities		
(a) Short-term borrowings	3728	2437
(b) Trade payables	3504	4684
(c) Other current liabilities	2333	2056
(d) Short-term provisions	12	12
Total	9577	9189
TOTAL	30458	29305
II. ASSETS		
1. Non-current assets		
(a) Fixed Assets		
(i) Tangible assets	10347	10618
(ii) Capital work-in-progress	84	93
(b) Non-current investment	687	607
(c) Long-term loans and advances	5067	5597
Total	16985	16995
2. Current assets		
(a) Inventories	4767	3674
(b) Trade receivables	3973	4961
(c) Cash and Bank balances	468	363
(d) Short term loans and advances	4265	3312
Total	13473	12310
TOTAL	30458	29305
KOPRAN LIMITED		
 Surendra Somani Executive Vice Chairman		
Place: Mumbai		
Date: 13-11-2013		



BATLIBOI & PUROHIT**CHARTERED ACCOUNTANTS****REVIEW REPORT TO THE BOARD OF DIRECTORS OF
KOPRAN LIMITED**

1) We have reviewed the accompanying statement of unaudited financial results of **Kopran Limited ("the Company")** for the quarter ended 30th September, 2013 except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding" which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

2) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the independent Auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3) *Attention is invited regarding Investment and Advances aggregating Rs. 500.61 lakhs and Rs. 4,736.62 lakhs respectively given to a subsidiary company, Kopran Research Laboratories Limited whose accumulated losses have exceeded the net-worth, no provision for Investments and Doubtful Advances has been made by the management of the Company. Consequently, the effect, if any, on the carrying values of investments and advances given are currently unascertainable.*

4) Based on our review conducted and *subject to our comments in para 3 above*, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, [notified pursuant to the Company's (Accounting Standards) Rules, 2006 as (amended)] and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BATLIBOI & PUROHIT

Chartered Accountants

Firm Reg No. 101048W



Kaushal Mehta

Kaushal Mehta

Partner

Membership No. 111749

Place : Mumbai

Dated : 13th November, 2013